£65.95m
0.000p
15.25p
IQE PLC
15 April 2008
IQE plc
15 April 2008
IQE plc (the 'Company')
Additional Listing
Application has been made to the London Stock Exchange for 994,657 ordinary
shares of 1p each in the Company ('Ordinary Shares') to be admitted to trading
on AIM. The Ordinary Shares are being issued pursuant to the exercise of share
options by certain employees under the IQE Group Share Option Scheme. The
Ordinary Shares are issued at the following prices:
Price of issue Number of Ordinary Shares
Total at 1.000p 2,000
Total at 5.633p 268,444
Total at 6.533p 23,520
Total at 6.670p 699,193
Total at 8.000p 1,500
TOTAL 994,657
Admission of these Ordinary Shares is expected to become effective on 18 April
2008.
Following this issue the total number of Ordinary Shares in issue will be
432,037,854.
Contacts:
IQE plc +44 29 2083 9400
Drew Nelson
Phil Rasmussen
Chris Meadows
College Hill +44 20 7457 2020
Adrian Duffield/ Ben Way
Noble & Company Limited +44 20 7763 2200
John Llewellyn-Lloyd/ Sam Reynolds
Panmure Gordon (UK) Limited +44 20 7459 3600
Aubrey Powell/ Ashton Clanfield
NOTE TO EDITORS
IQE plc is the leading global supplier of advanced semiconductor wafers with
products that cover a diverse range of applications. It is able to provide a
'one stop shop' for the wafer needs of the world's leading compound
semiconductor manufacturers, who in turn use these wafers to make the chips
which form the key components of virtually every high technology system. IQE has
particular focus on the growing global wireless sector for applications
including; mobile handsets, wireless infrastructure, Wi-Fi, WiMAX, base
stations, GPS and satellite communications; as well as for the optical
communication sector including; optical storage (CD, DVD), laser optical mice,
laser printers & photocopiers, thermal imagers, leading-edge medical products,
bar-coding, high efficiency LEDs and advanced solar cells.
The manufacturers of these chips are increasingly seeking to outsource wafer
production to specialist foundries such as IQE in order to reduce overall wafer
costs and accelerate time to market. IQE is unique in being able to supply
wafers using all of the leading crystal growth technology platforms including
Metal Organic Vapour Phase Epitaxy (MOVPE) and Molecular Beam Epitaxy (MBE) and
the Group is able to leverage its global purchasing volumes to reduce the cost
of raw materials.
IQE also provides bespoke R&D services to deliver customized materials for
specific applications and offers specialist technical staff to manufacture to
specification either at its own facilities or on the customer's own sites. This
is backed by a strategy of duplicating each key product processes over multiple
sites to assure customers of security of supply as well as provide compelling
customer benefits in terms of flexibility and predictability of cost, thereby
significantly reducing operating risk.
IQE operates six manufacturing facilities; two in Cardiff and one in Milton
Keynes in the UK; two more in Bethlehem, Pennsylvania and Somerset, New Jersey
in the USA; and its most recent acquisition in Singapore. The Group also has 11
sales offices located in major economic centres worldwide.
This information is provided by RNS
The company news service from the London Stock Exchange